| Pharmaceutical Business Review | Merck's Keytruda fails to improve survival in phase 3 head and neck ... Pharmaceutical Business Review Merck's anti-PD-1 therapy Keytruda (pembrolizumab) failed to improve overall survival (OS) in a pivotal phase 3 trial in head and neck squamous cell c. Keytruda fails confirmatory trial, but Merck says FDA will not pull ...The Pharma Letter (registration) Healthcare Giants In Focus; Pfizer Inc. (PFE) and Merck & Co., Inc ...Investing News Update all 3 news articles » |
from # All Medicine by Alexandros G. Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2tEbJYT
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Medicine by Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00302841026182,00306932607174,alsfakia@gmail.com,